ISCT Hails Landmark US FDA Approval of RYONCIL as Major Milestone for MSC Field [Yahoo! Finance]
Mesoblast Limited - American Depositary Shares (MESO)
US:NASDAQ Investor Relations:
investorsmedia.mesoblast.com
Company Research
Source: Yahoo! Finance
Graft-versus-Host-Disease (GvHD). This is the first FDA approval of an MSC therapy in the US, marking a significant milestone for the field. RYONCIL will provide a treatment option for pediatric patients who do not respond to first-line steroid treatment, addressing a significant unmet need. The approval is based on a Phase III trial showing a 70.4% overall response rate at day 28, compared to a preset control group of 45%. Generated by Yahoo Finance AI Yahoo Finance used generative AI to summarize key information from this article. Some details may be inaccurate. We take that seriously. Reporting mistakes helps us improve these summaries. Was this helpful? Yes No VANCOUVER, BC Dec. 20, 2024 /PRNewswire/ - The International Society for Cell & Gene Therapy (ISCT) celebrates the US Food and Drug Administration's (FDA) landmark decision to approve Mesoblast Limited's allogenic, bone marrow-derived mesenchymal stromal cell (MSC) product, RYONCIL® (remestemcel-L) for pediatric,
Show less
Read more
Impact Snapshot
Event Time:
MESO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MESO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MESO alerts
High impacting Mesoblast Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MESO
News
- Mesoblast Limited (NASDAQ: MESO) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating.MarketBeat
- Mesoblast Limited (NASDAQ: MESO) had its price target raised by analysts at Piper Sandler from $11.00 to $15.00. They now have an "overweight" rating on the stock.MarketBeat
- Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease [Yahoo! Finance]Yahoo! Finance
- How has the FDA approval of Ryoncil affected Mesoblast's stock price? [Yahoo! Finance]Yahoo! Finance
- Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) TherapyGlobeNewswire